EyePoint Pharmaceuticals, Inc.
Watertown, United States
- Website not added yet
- LinkedIn not added yet
- X not added yet
- Instagram not added yet
- Facebook not added yet
EyePoint Pharmaceuticals, Inc was founded by Michael Rogers, Kristine Peterson, David Mazzo, Dario S. Paggiarino, Leonard S. Ross, Douglas Godshall, Jay Duker, Ronald W. Eastman, Nancy Lurker, James Barry, Scott Jones, Dario Paggiarino, M.D., Goran Ando, George O. Elston, Wendy O. DiCicco, Douglas W. Godshall, David R. Guyer, M.D., John R. Landis, Ph.D., M.S. and Ye R. Liu, and is based in Watertown, United States.
Key facts
- Industry
- Pharmaceuticals
- Legal form
- Incorporated in Delaware
- Listed
- Nasdaq · EYPT
About
Laboratory Analytical Instruments; formerly EyePoint Pharmaceuticals, Inc.; listed on Nasdaq as EYPT; filing with the SEC since 2009
Founders
Director
1500 Founder Rating
Director
1500 Founder Rating
Director
1500 Founder Rating
Vice President, Chief Medical Officer
1500 Founder Rating
Vice President, Finance and Chief Accounting Officer
1500 Founder Rating
Director
1500 Founder Rating
Director
1500 Founder Rating
Director
1500 Founder Rating
President and Chief Executive Officer
1500 Founder Rating
Director
1500 Founder Rating
Chief Commercial Officer
1500 Founder Rating
Senior Vice President and Chief Medical Officer
1500 Founder Rating
Director
1500 Founder Rating
Chief Financial Officer and Head of Corporate Development
1500 Founder Rating
Director
1500 Founder Rating
Director
1500 Founder Rating
Director
1500 Founder Rating
Director
1500 Founder Rating
Director
1500 Founder Rating
In context
We hold 687 other pharmaceuticals companies. None has a closure on record yet. Of the 638 that report what they raised, the median is $4,127,748.
Counted across this directory, from founding and closing years in public records. Medians cover only companies whose closure is recorded; a company with no closure date may have quietly ceased without the record catching it.
Discussion
Log in to join the discussion and like comments.
Log In to Comment